A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan
NCT06684314
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Interventions
DRUG:
Efanesoctocog alfa
Sponsor
Sanofi